Skip to Main Content

Rise and shine, everyone, the middle of the week is here. You made it this far, so why not forge ahead, yes? As always, we are doing our best with the help of some cups of stimulation — we are quaffing pistachio creme this morning — and invite you to join us. After all, a prescription is not required, so go ahead and indulge. Meanwhile, we have assembled the latest menu of tidbits to get you started on another busy day. Hope all goes well and you conquer the world. Cheers. …

Covid-19 vaccine makers have dialed up lobbying and public relations efforts to rally opposition to a proposal to temporarily waive their patents, The Wall Street Journal reports. Industry lobbyists have met with Biden administration officials to argue for alternative actions and have been lobbying members of Congress to pressure the administration to reverse its support of the waiver. Lobbyists have also told other governments, in meetings and phone calls, that a waiver would not address shortages any time soon, but would strain raw material supplies.


The Food and Drug Administration may decline to review and process new emergency use authorization requests for Covid-19 vaccines for the rest of the pandemic, if a company has not already begun discussions, Reuters writes. So far, vaccines from Pfizer (PFE) and BioNTech (BNTX), Moderna (MRNA), and Johnson & Johnson (JNJ) have been authorized for emergency use in the U.S. Novavax (NVAX) has had discussions with regulators, but does not expect to seek regulatory authorization in the U.S., the U.K., and Europe until the third quarter of 2021.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!